查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球数位病理市场的市场规模、份额和趋势：按产品类型、应用和最终用户划分 - 预测（截至 2029 年）
市场调查报告书
商品编码
1520993

全球数位病理市场的市场规模、份额和趋势：按产品类型、应用和最终用户划分 - 预测（截至 2029 年）

Digital Pathology Market Size, Share & Trends by Product, Type, Application, End User - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 317 Pages | 订单完成后即时交付

价格

全球数位病理市场规模预计将从2024年的11亿美元增加至2029年的20亿美元，2024年至2029年的复合年增长率为13.1%。

高解析度扫描仪、先进成像软体和人工智慧分析等技术进步推动了市场成长，这些技术显着提高了病理工作流程的准确性和效率。包括癌症在内的慢性疾病的增加需要快速、准确的诊断工具，而数位病理学可以轻鬆提供这些工具。此外，推进个人化医疗和标靶治疗需要数位病理学可以提供的详细组织分析。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
单元 10亿美元
部分 产品类型、应用程式和最终用户
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东非洲

“在预测期内，扫描器细分市场占据了最大的市场份额。”

到 2023 年，扫描仪将在该产品领域占据最大份额，因为它们是数位病理过程的重要设备。扫描器将载玻片转换为高解析度数位影像，病理学家可在电脑萤幕上检视和分析检体。扫描仪在实现远距离诊断方面的关键作用正在推动需求，因为扫描仪使病理学家能够从任何位置检查病例，从而提高病理服务的可及性和效率。此外，扫描器技术的进步，例如更高解析度的影像和更快的扫描速度，提高了诊断准确性和工作流程效率，使其成为实验室和医疗机构的一项值得投资。

“按类型划分，人类病理学将在预测期内占据最大份额。”

人类病理学在预测期内占最大份额。首先，癌症等慢性病的盛行率不断上升，需要先进的诊断工具来准确、及时地检测。与传统方法相比，数位病理学具有显着优势，包括增强的影像分析、卓越的储存和搜寻功能以及轻鬆共用数位切片以进行远端会诊和第二意见。此外，人工智慧和机器学习等技术进步越来越多地融入数位病理学中，为病理学家提供了提高诊断准确性和效率的强大工具。

“在预测期内，药物发现领域占据了最大的市场份额。”

2023年，药物发现领域在应用领域中占最大份额。这是由于药物开发过程的精确性。因此，将数位病理测试纳入药物发现工作流程可显着提高生产力，加速创新，并缩短新药的上市时间，使其在该细分市场中占据稳固的主导地位。

“製药和生物技术公司是市场最大的最终用户。”

2023年，製药和生物技术公司占最大份额。数位病理学解决方案的可扩展性非常适合製药和生物技术公司处理的大样本量，为加速研究和开发并最终将新治疗方法推向市场提供了重要工具，这将导致缩短时间。这种效率、准确性和协作的提高相结合，使数位病理学成为这些公司的宝贵资产，推动了他们的主导市场占有率。

本报告研究和分析了全球数位病理市场，提供了关键驱动因素和限制因素、竞争格局和未来趋势等资讯。

目录

第一章 简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

  • 数位病理市场概述
  • 北美数位病理市场：依最终用户、按国家分类 (2023)
  • 数位病理市场：地理成长机会
  • 数位病理市场：区域构成

第五章市场概况

  • 介绍
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 产业动态
    • 远端病理学
    • 多路復用
  • 技术分析
    • 主要技术
    • 邻近技术
    • 互补技术
  • 价格分析
    • 平均销售价格趋势：按地区
    • 主要企业平均售价趋势：依产品分类
  • 价值链分析
  • 生态系分析
  • 波特五力分析
  • 监管环境
    • 监管机构、政府机构和其他组织
    • 监管分析
  • 数位病理扫描仪的HS编码
  • 专利分析
  • 案例研究分析
  • 重大会议和活动（2024-2025）
  • 主要相关利益者和采购标准
  • 最终用户分析
    • 未满足的需求
    • 最终用户的期望
  • 经营模式分析
  • 投资金筹措场景
  • 生成式人工智慧对数位病理市场的影响
    • 主要用例和市场未来性
    • 生成式人工智慧实施案例研究
    • 使用者准备和影响评估

第六章数位病理市场：依产品

  • 介绍
  • 扫描器
    • 明场扫描仪
    • 萤光扫描仪
    • 其他扫描仪
  • 软体：依类型
    • 整合软体
    • 独立软体
  • 软体：按部署模型
    • 云端基础模式
    • 本地部署模式
    • 混合模式
  • 储存系统

第七章数字病理市场：按类型

  • 介绍
  • 人类病理学
  • 兽医病理学

第八章数位病理市场：依应用分类

  • 介绍
  • 药物发现
  • 疾病诊断
  • 培训/教育

第 9 章 数位病理学市场：依最终用户分类

  • 介绍
  • 製药和生物技术公司
  • 医院/参考实验室
  • 学术/研究机构

第10章数字病理市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 瑞典
    • 丹麦
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东/非洲

第十一章竞争格局

  • 概述
  • 主要企业策略/主要企业
  • 收益分析
  • 市场占有率分析
  • 企业评价矩阵：主要企业（2023年）
  • 公司评估矩阵：Start-Ups/中小企业（2023）
  • 评价及财务指标
  • 品牌/软体比较分析
  • 竞争场景

第十二章 公司简介

  • 主要企业
    • DANAHER CORPORATION
    • KONINKLIJKE PHILIPS NV
    • HAMAMATSU PHOTONICS KK
    • F. HOFFMANN-LA ROCHE LTD.
    • SECTRA AB
    • AKOYA BIOSCIENCES, INC.
    • FUJIFILM HOLDINGS CORPORATION
    • HOLOGIC, INC.
    • 3DHISTECH LTD.
    • APOLLO ENTERPRISE IMAGING CORP.
    • XIFIN, INC.
    • HURON DIGITAL PATHOLOGY
    • CORISTA
    • INDICA LABS
    • OBJECTIVE PATHOLOGY SERVICES
    • OPTRASCAN, INC.
    • GLENCOE SOFTWARE, INC.
    • AIFORIA TECHNOLOGIES OY
    • PAIGE AI, INC.
    • PROSCIA, INC.
  • 其他公司
    • PATHAI
    • KONFOONG BIOTECH INTERNATIONAL CO., LTD.
    • MIKROSCAN TECHNOLOGIES, INC.
    • MOTIC DIGITAL PATHOLOGY
    • KANTERON SYSTEMS
    • MORPHLE LABS INC.

第十三章附录

Product Code: HIT 2608

The global digital pathology market is projected to reach USD 2.0 billion by 2029 from USD 1.1 billion in 2024, at a CAGR of 13.1% from 2024 to 2029. The growth of the market is fuelled due to advancements in technology, such as high-resolution scanners, sophisticated imaging software, and AI-powered analytics, significantly improve the accuracy and efficiency of pathology workflows. The increasing prevalence of chronic diseases, including cancer, necessitates rapid and precise diagnostic tools, which digital pathology readily provides. Moreover, the push towards personalized medicine and targeted therapies requires detailed tissue analysis that digital pathology can deliver.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD Billion)
SegmentsProduct, Type, Application, and End user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East Africa.

"Scanners segment held the largest share in the global Digital Pathology market during the forecast period."

On the basis type, the Digital Pathology market is segmented into scanners, software, and storage systems segment. The scanners segment accounted for the largest share of the product segment in 2023 because these devices are essential to the digital pathology process. Scanners transform glass slides into high-resolution digital images, allowing pathologists to view and analyze specimens on computer screens. The critical role of scanners in enabling remote diagnostics drives their demand, as they allow pathologists to review cases from any location, thereby improving accessibility and efficiency in pathology services. Furthermore, advancements in scanner technology, such as higher resolution imaging and faster scanning speeds, enhance diagnostic accuracy and workflow efficiency, making them a valuable investment for laboratories and healthcare facilities.

"By type, human pathology holds the largest share during the forecast period."

Based on type, the Digital Pathology market is segmented into human pathology and veterinary pathology. Human pathology holds the largest share during forecast period. Firstly, the rising prevalence of chronic diseases such as cancer demands advanced diagnostic tools for accurate and timely detection. Digital pathology offers significant advantages over traditional methods, including enhanced image analysis, superior storage and retrieval capabilities, and the ease of sharing digital slides for remote consultations and second opinions. Moreover, technological advancements like artificial intelligence and machine learning are increasingly being integrated into digital pathology, equipping pathologists with powerful tools for improved diagnostic accuracy and efficiency.

"The Drug Discovery segment accounted for the largest share of the global Digital Pathology market during the forecast period."

Based on application, the Digital Pathology market is segmented into drug discovery, disease diagnosis, training and education segment. The drug discovery segment accounted for the largest share of the application segment in 2023. This is due to the accuracy of the drug development process. Consequently, integrating digital pathology into drug discovery workflows significantly boosts productivity, drives innovation, and shortens the time-to-market for new drugs, cementing its dominant position in this market segment.

"Pharmaceutical and biotechnology companies are largest end users of the Digital Pathology market."

Based on end users, the Digital Pathology market is segmented into pharmaceutical and biotechnology companies, hospital and reference laboratories, and academic and research institutes. The pharmaceutical and biotechnology companies held the largest share in 2023. The scalability of digital pathology solutions aligns well with the large volumes of samples that pharmaceutical and biotechnology companies handle, providing them with a critical tool to accelerate research and development, ultimately leading to faster time-to-market for new therapies. This combination of improved efficiency, accuracy, and collaboration makes digital pathology an invaluable asset for these companies, thus driving their dominant market share.

"North America dominates the global Digital Pathology market."

The Digital Pathology market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2023, North America accounted for the largest share of the Digital Pathology market. This is due to its advanced healthcare infrastructure and significant investment in healthcare technologies, allowing for the adoption of cutting-edge digital pathology systems. Also, regulatory frameworks in countries like the US and Canada are supportive of the adoption of advanced medical technologies, ensuring a streamlined approval process for digital pathology solutions.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
  • By Designation: C-level (35%), Director-level (25%), and Others (40%)
  • By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report

    • Danaher Corporation (US)
    • Koninklijke Philips N.V. (Netherlands)
    • Hamamatsu Photonics K.K. (Japan)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • 3DHISTECH (Hungary)
    • Apollo Enterprise Imaging (US)
    • XIFIN, Inc. (US)
    • Huron Digital Pathology (Canada)
    • Hologic, Inc. (US)
    • Corista (US)
    • Indica Labs Inc. (US)
    • Objective Pathology Services Limited (Canada)
    • Sectra AB (Sweden)
    • OptraSCAN (US)
    • Akoya Biosciences, Inc. (US)
    • Glencoe Software, Inc. (US)
    • Aiforia (Finland)
    • Paige AI, Inc. (US)
    • Fujifilm Holdings Corporation (Japan)
    • Proscia Inc. (US)
    • KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China)
    • Mikroscan Technologies, Inc. (US)
    • PathAI (US)
    • Motic Digital Pathology (US)
    • Kanteron Systems (Spain)

Research Coverage

This report studies the digital pathology market based on product, type, application, end user, and region. The report also analyses factors (such as drivers, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total digital pathology market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

  • Analysis of key drivers (advancements in image analysis algorithms, artificial intelligence (AI) applications for pattern recognition, and cloud-based solutions that enhance scalability and accessibility), restrains (lack of trained pathologits and high capital investment), challenges (data privacy concerns), opportunities (expansion in emerging market and personalized medicine and biomarker discovery) are contributing the growth of the digital pathology market.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the digital pathology market.
  • Market Development: Comprehensive information on the lucrative emerging markets, products, type, application, end-user, and region.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the digital pathology market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global digital pathology Market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 RESEARCH METHODOLOGY DESIGN
  • 2.3 MARKET SIZE ESTIMATION
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 MARKET ASSUMPTIONS
    • 2.6.1 OVERALL STUDY ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
  • 2.8 RESEARCH LIMITATIONS
    • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 DIGITAL PATHOLOGY MARKET OVERVIEW
  • 4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER & COUNTRY (2023)
  • 4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 DIGITAL PATHOLOGY MARKET: REGIONAL MIX

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of cancer and chronic diseases
      • 5.2.1.2 Increasing adoption of digital pathology solutions to enhance lab efficiency
      • 5.2.1.3 Growing applications in drug development and companion diagnostics
      • 5.2.1.4 Rising awareness of early cancer diagnosis in emerging markets
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of digital pathology systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Introduction of affordable scanners for private pathology practices
      • 5.2.3.2 Growing preference for personalized medicine
      • 5.2.3.3 High growth potential of emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of skilled pathologists
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 TELEPATHOLOGY
    • 5.3.2 MULTIPLEXING
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 AI in digital pathology
      • 5.4.1.2 Label-free imaging in digital pathology
      • 5.4.1.3 Computational image analysis in digital pathology
    • 5.4.2 ADJACENT TECHNOLOGIES
      • 5.4.2.1 Genomic sequencing
    • 5.4.3 COMPLEMENTARY TECHNOLOGIES
      • 5.4.3.1 Molecular imaging
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
    • 5.5.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY LANDSCAPE
    • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.9.2 REGULATORY ANALYSIS
      • 5.9.2.1 North America
        • 5.9.2.1.1 US
        • 5.9.2.1.2 Canada
      • 5.9.2.2 Europe
      • 5.9.2.3 Asia Pacific
        • 5.9.2.3.1 Japan
        • 5.9.2.3.2 China
        • 5.9.2.3.3 India
  • 5.10 HS CODES FOR DIGITAL PATHOLOGY SCANNERS
  • 5.11 PATENT ANALYSIS
    • 5.11.1 PATENT PUBLICATION TRENDS
    • 5.11.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS
    • 5.11.3 MAJOR PATENTS
  • 5.12 CASE STUDY ANALYSIS
  • 5.13 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 BUYING CRITERIA
  • 5.15 END-USER ANALYSIS
    • 5.15.1 UNMET NEEDS
    • 5.15.2 END-USER EXPECTATIONS
  • 5.16 BUSINESS MODEL ANALYSIS
  • 5.17 INVESTMENT & FUNDING SCENARIO
  • 5.18 IMPACT OF GENERATIVE AI ON DIGITAL PATHOLOGY MARKET
    • 5.18.1 TOP USE CASES & MARKET POTENTIAL
      • 5.18.1.1 Key Use Cases
    • 5.18.2 CASE STUDIES OF GENERATIVE AI IMPLEMENTATION
      • 5.18.2.1 Case Study 1: Healthcare - Enhancing Medical Imaging
      • 5.18.2.2 Case study 2: Combining generative AI with biosensors and lab-on-a-chip technology
      • 5.18.2.3 Case study 3: Impact of Gen AI-based Digital pathology: the Korean experience
      • 5.18.2.4 AI in pathology market
      • 5.18.2.5 Tissue diagnostics market
      • 5.18.2.6 Anatomic pathology market
    • 5.18.3 USER READINESS AND IMPACT ASSESSMENT
      • 5.18.3.1 User readiness
        • 5.18.3.1.1 Pharmaceutical & biotechnology companies
        • 5.18.3.1.2 Hospitals & reference laboratories
        • 5.18.3.1.3 Academic & research institutes
      • 5.18.3.2 Impact assessment
        • 5.18.3.2.1 Pharmaceutical & biotechnology companies
        • 5.18.3.2.2 Hospitals & reference laboratories
        • 5.18.3.2.3 Academic & research institutes

6 DIGITAL PATHOLOGY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 SCANNERS
    • 6.2.1 BRIGHTFIELD SCANNERS
      • 6.2.1.1 Cost-efficient features to boost demand
    • 6.2.2 FLUORESCENCE SCANNERS
      • 6.2.2.1 Ability to detect cellular structures and biomarkers to fuel uptake
    • 6.2.3 OTHER SCANNERS
  • 6.3 SOFTWARE, BY TYPE
    • 6.3.1 INTEGRATED SOFTWARE
      • 6.3.1.1 Single & effective suite for multiple applications to propel market
    • 6.3.2 STANDALONE SOFTWARE
      • 6.3.2.1 Information management software
        • 6.3.2.1.1 Management of image repositories to fuel uptake
      • 6.3.2.2 Image analysis software
        • 6.3.2.2.1 Ability to automate quantitative evaluation to support market growth
  • 6.4 SOFTWARE, BY DEPLOYMENT MODEL
    • 6.4.1 CLOUD-BASED MODEL
      • 6.4.1.1 Benefits of cloud-based models and ease of access to drive market
    • 6.4.2 ON-PREMISE MODEL
      • 6.4.2.1 High data security and integration with HCIT solutions to fuel uptake
    • 6.4.3 HYBRID MODEL
      • 6.4.3.1 Combined flexibility to support market growth
  • 6.5 STORAGE SYSTEMS
    • 6.5.1 GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET

7 DIGITAL PATHOLOGY MARKET, BY TYPE

  • 7.1 INTRODUCTION
  • 7.2 HUMAN PATHOLOGY
    • 7.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET
  • 7.3 VETERINARY PATHOLOGY
    • 7.3.1 IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH

8 DIGITAL PATHOLOGY MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 DRUG DISCOVERY
    • 8.2.1 INCREASING FOCUS ON LIFE SCIENCES R&D TO DRIVE MARKET
  • 8.3 DISEASE DIAGNOSIS
    • 8.3.1 INTEGRATION OF AI & ML IN COMPLEX DIAGNOSTICS TO BOOST DEMAND
  • 8.4 TRAINING & EDUCATION
    • 8.4.1 ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH

9 DIGITAL PATHOLOGY MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET
  • 9.3 HOSPITALS AND REFERENCE LABORATORIES
    • 9.3.1 HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH

10 DIGITAL PATHOLOGY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 US
      • 10.2.1.1 Favorable reimbursements for diagnostics to drive market
    • 10.2.2 CANADA
      • 10.2.2.1 Growing awareness of early cancer detection & diagnosis to drive market
  • 10.3 EUROPE
    • 10.3.1 GERMANY
      • 10.3.1.1 High healthcare expenditure and supportive research initiatives to drive market
    • 10.3.2 UK
      • 10.3.2.1 Government funding investments for pathology services to fuel market
    • 10.3.3 SWEDEN
      • 10.3.3.1 Increasing prevalence of chronic diseases to support market growth
    • 10.3.4 DENMARK
      • 10.3.4.1 Increasing deployment of digital pathology solutions to support market growth
    • 10.3.5 FRANCE
      • 10.3.5.1 Increasing government funding and favorable insurance system to drive adoption
    • 10.3.6 SPAIN
      • 10.3.6.1 Supportive collaborations among leading companies and hospitals to boost demand
    • 10.3.7 ITALY
      • 10.3.7.1 Integration of AI & ML to support market growth
    • 10.3.8 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 CHINA
      • 10.4.1.1 Increasing establishment of hospitals and reference laboratories to drive market
    • 10.4.2 JAPAN
      • 10.4.2.1 Advanced healthcare infrastructure to support market growth
    • 10.4.3 INDIA
      • 10.4.3.1 Growth in pharmaceutical industry to propel market
    • 10.4.4 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 BRAZIL
      • 10.5.1.1 High adoption of POC testing to drive market
    • 10.5.2 MEXICO
      • 10.5.2.1 Growth in companion diagnostics to fuel uptake
    • 10.5.3 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    • 10.6.2 GCC COUNTRIES
    • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET
  • 11.3 REVENUE ANALYSIS
  • 11.4 MARKET SHARE ANALYSIS
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Product footprint
      • 11.5.5.2 Application footprint
      • 11.5.5.3 End-user footprint
      • 11.5.5.4 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 VALUATION & FINANCIAL METRICS
  • 11.8 BRAND/SOFTWARE COMPARATIVE ANALYSIS
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
    • 11.9.2 DEALS
    • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY COMPANIES
    • 12.1.1 DANAHER CORPORATION
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product enhancements
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Key strengths
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 KONINKLIJKE PHILIPS N.V.
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Product launches
        • 12.1.2.3.2 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Key strengths
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses and competitive threats
    • 12.1.3 HAMAMATSU PHOTONICS K.K.
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Product approvals
        • 12.1.3.3.2 Deals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses and competitive threats
    • 12.1.4 F. HOFFMANN-LA ROCHE LTD.
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Product Launches & approvals
        • 12.1.4.3.2 Deals
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Key strengths
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses and competitive threats
    • 12.1.5 SECTRA AB
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Deals
        • 12.1.5.3.2 Other developments
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Key strengths
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses and competitive threats
    • 12.1.6 AKOYA BIOSCIENCES, INC.
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Product Launches & approvals
        • 12.1.6.3.2 Deals
    • 12.1.7 FUJIFILM HOLDINGS CORPORATION
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Deals
    • 12.1.8 HOLOGIC, INC.
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Product approvals
    • 12.1.9 3DHISTECH LTD.
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Product launches & enhancements
        • 12.1.9.3.2 Other developments
    • 12.1.10 APOLLO ENTERPRISE IMAGING CORP.
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Product enhancements
        • 12.1.10.3.2 Deals
    • 12.1.11 XIFIN, INC.
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products offered
      • 12.1.11.3 Recent developments
        • 12.1.11.3.1 Product launches
        • 12.1.11.3.2 Deals
    • 12.1.12 HURON DIGITAL PATHOLOGY
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products offered
      • 12.1.12.3 Recent developments
        • 12.1.12.3.1 Product approvals
        • 12.1.12.3.2 Deals
        • 12.1.12.3.3 Other developments
    • 12.1.13 CORISTA
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products offered
      • 12.1.13.3 Recent developments
        • 12.1.13.3.1 Deals
        • 12.1.13.3.2 Other developments
    • 12.1.14 INDICA LABS
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products offered
      • 12.1.14.3 Recent developments
        • 12.1.14.3.1 Product launches & approvals
        • 12.1.14.3.2 Deals
    • 12.1.15 OBJECTIVE PATHOLOGY SERVICES
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products offered
    • 12.1.16 OPTRASCAN, INC.
      • 12.1.16.1 Business overview
      • 12.1.16.2 Products offered
      • 12.1.16.3 Recent developments
        • 12.1.16.3.1 Product launches & approvals
        • 12.1.16.3.2 Deals
    • 12.1.17 GLENCOE SOFTWARE, INC.
      • 12.1.17.1 Business overview
      • 12.1.17.2 Products offered
      • 12.1.17.3 Recent developments
        • 12.1.17.3.1 Product enhancements
    • 12.1.18 AIFORIA TECHNOLOGIES OY
      • 12.1.18.1 Business overview
      • 12.1.18.2 Products offered
      • 12.1.18.3 Recent developments
        • 12.1.18.3.1 Deals
    • 12.1.19 PAIGE AI, INC.
      • 12.1.19.1 Business overview
      • 12.1.19.2 Products offered
      • 12.1.19.3 Recent developments
        • 12.1.19.3.1 Product launches & enhancements
        • 12.1.19.3.2 Deals
    • 12.1.20 PROSCIA, INC.
      • 12.1.20.1 Business overview
      • 12.1.20.2 Products offered
      • 12.1.20.3 Recent developments
        • 12.1.20.3.1 Product enhancements & approvals
        • 12.1.20.3.2 Deals
  • 12.2 OTHER PLAYERS
    • 12.2.1 PATHAI
    • 12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD.
    • 12.2.3 MIKROSCAN TECHNOLOGIES, INC.
    • 12.2.4 MOTIC DIGITAL PATHOLOGY
    • 12.2.5 KANTERON SYSTEMS
    • 12.2.6 MORPHLE LABS INC.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 FACTOR ANALYSIS
  • TABLE 2 RISK ASSESSMENT
  • TABLE 3 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
  • TABLE 4 US: GROWTH IN NUMBER OF PERSONALIZED MEDICINES (2008-2020)
  • TABLE 5 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020
  • TABLE 6 AVERAGE SELLING PRICE TREND OF DIGITAL PATHOLOGY PRODUCTS, BY REGION
  • TABLE 7 AVERAGE SELLING PRICE OF DIGITAL PATHOLOGY PRODUCTS
  • TABLE 8 DIGITAL PATHOLOGY MARKET: PORTER'S FIVE FORCES
  • TABLE 9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 13 EUROPE: CLASSIFICATION OF IVD DEVICES
  • TABLE 14 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 16 HS CODE: DIGITAL PATHOLOGY SCANNER
  • TABLE 17 CASE STUDY 1: ASSESSING IMAGE QUALITY FOR COMPARATIVE MULTI-ASSESSMENT EVALUATION OF APERIO GT 450 DX
  • TABLE 18 CASE STUDY 2: PROMOTION OF PATHOLOGY WORKFLOW EFFICIENCY
  • TABLE 19 CASE STUDY 3: INTEGRATION OF ARTIFICIAL INTELLIGENCE IN DIGITAL PATHOLOGY
  • TABLE 20 DIGITAL PATHOLOGY MARKET: KEY CONFERENCES & EVENTS, 2024-2025
  • TABLE 21 STAKEHOLDERS IN BUYING PROCESS: DEFINITIONS
  • TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DIGITAL PATHOLOGY, BY PRODUCT
  • TABLE 23 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
  • TABLE 24 UNMET NEEDS IN DIGITAL PATHOLOGY MARKET
  • TABLE 25 END-USER EXPECTATIONS IN DIGITAL PATHOLOGY MARKET
  • TABLE 26 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 27 SCANNING MAGNIFICATION AND APPLICATIONS
  • TABLE 28 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS
  • TABLE 29 DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 30 DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS
  • TABLE 32 BRIGHTFIELD SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 FLUORESCENCE SCANNERS OFFERED BY KEY MARKET PLAYERS
  • TABLE 34 FLUORESCENCE SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS
  • TABLE 36 OTHER SCANNERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 38 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 39 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 41 INTEGRATED SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 43 STANDALONE SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 45 INFORMATION MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 47 IMAGE ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 49 CLOUD-BASED SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 50 CLOUD-BASED MODEL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 ON-PREMISE SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 52 ON-PREMISE MODEL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 HYBRID SOFTWARE OFFERED BY KEY MARKET PLAYERS
  • TABLE 54 HYBRID MODEL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS
  • TABLE 56 DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 58 HUMAN DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 VETERINARY DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 61 SOFTWARE IMPACT ANALYSIS, BY APPLICATION
  • TABLE 62 DIGITAL PATHOLOGY APPLICATIONS IN DRUG DISCOVERY
  • TABLE 63 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 67 SOFTWARE IMPACT ANALYSIS, BY END USER
  • TABLE 68 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS IN HOSPITALS
  • TABLE 70 DIGITAL PATHOLOGY MARKET FOR HOSPITALS AND REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 DIGITAL PATHOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 75 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 76 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 77 NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 81 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 82 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 83 US: KEY MACROINDICATORS
  • TABLE 84 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 85 US: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 86 US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 87 US: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 88 US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 89 US: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 90 US: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 91 US: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 92 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 93 CANADA: FUNDING INITIATIVES FOR DIGITAL PATHOLOGY
  • TABLE 94 CANADA: KEY MACROINDICATORS
  • TABLE 95 CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 96 CANADA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 97 CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 98 CANADA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 99 CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 100 CANADA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 101 CANADA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 102 CANADA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 103 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 104 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 105 EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 106 EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 107 EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 108 EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 109 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 110 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 111 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 112 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 113 GERMANY: KEY MACROINDICATORS
  • TABLE 114 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 115 GERMANY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 116 GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 117 GERMANY: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 118 GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 119 GERMANY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 120 GERMANY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 121 GERMANY: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 122 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
  • TABLE 123 UK: KEY MACROINDICATORS
  • TABLE 124 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 125 UK: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 126 UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 127 UK: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 128 UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 129 UK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 130 UK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 131 UK: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 132 SWEDEN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 133 SWEDEN: KEY MACROINDICATORS
  • TABLE 134 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 135 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 136 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 137 SWEDEN: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 138 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 139 SWEDEN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 140 SWEDEN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 141 SWEDEN: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 142 DENMARK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 143 DENMARK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 144 DENMARK: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 145 DENMARK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 146 DENMARK: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 147 DENMARK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 148 DENMARK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 149 DENMARK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 150 DENMARK: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 151 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 152 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 153 FRANCE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 155 FRANCE: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 156 FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 157 FRANCE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 FRANCE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 159 FRANCE: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 160 SPAIN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 161 SPAIN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 162 SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 163 SPAIN: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 164 SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 165 SPAIN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 166 SPAIN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 167 SPAIN: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 168 ITALY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 169 ITALY: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 170 ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 171 ITALY: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 172 ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 173 ITALY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 174 ITALY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 175 ITALY: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 176 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 177 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 178 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 179 REST OF EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 180 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 181 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 182 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 183 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 187 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 190 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 192 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 193 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 194 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 195 CHINA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 196 CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 197 CHINA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 198 CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 199 CHINA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 200 CHINA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 201 CHINA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 202 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 203 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 204 JAPAN: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 205 JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 206 JAPAN: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 207 JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 208 JAPAN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 209 JAPAN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 210 JAPAN: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 211 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 212 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 213 INDIA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 214 INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 215 INDIA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 216 INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 217 INDIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 218 INDIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 219 INDIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 220 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 221 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 222 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 223 REST OF ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 224 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 225 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 226 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 227 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 228 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 229 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 230 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 231 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 232 LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 233 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 234 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 235 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 236 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 237 BRAZIL: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 238 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 239 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 240 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 241 BRAZIL: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 242 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 243 BRAZIL: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 244 BRAZIL: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 245 BRAZIL: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 246 MEXICO: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 247 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 248 MEXICO: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 249 MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 250 MEXICO: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 251 MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 252 MEXICO: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 253 MEXICO: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 254 MEXICO: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 255 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 256 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 257 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 258 REST OF LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 259 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 260 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 261 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 262 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 263 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 264 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 265 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 266 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 267 MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 268 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 269 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 270 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 271 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 272 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 273 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 274 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 275 GCC COUNTRIES: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 276 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 277 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 278 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 279 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 280 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 281 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SCANNERS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 282 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 283 REST OF MIDDLE EAST & AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 284 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
  • TABLE 285 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 286 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 287 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 288 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 289 DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 290 DIGITAL PATHOLOGY MARKET: PRODUCT FOOTPRINT
  • TABLE 291 DIGITAL PATHOLOGY MARKET: APPLICATION FOOTPRINT
  • TABLE 292 DIGITAL PATHOLOGY MARKET: END-USER FOOTPRINT
  • TABLE 293 DIGITAL PATHOLOGY MARKET: REGION FOOTPRINT
  • TABLE 294 DIGITAL PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 295 DIGITAL PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 296 DIGITAL PATHOLOGY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2021-MARCH 2024
  • TABLE 297 DIGITAL PATHOLOGY MARKET: DIGITAL PATHOLOGY MARKET: DEALS, JANUARY 2021-MARCH 2024
  • TABLE 298 DIGITAL PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2024
  • TABLE 299 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 300 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 301 DANAHER CORPORATION: PRODUCT ENHANCEMENTS, JANUARY 2021-JUNE 2024
  • TABLE 302 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 303 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
  • TABLE 304 KONINKLIJKE PHILIPS N.V: PRODUCT LAUNCHES, JANUARY 2021-JUNE 2024
  • TABLE 305 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 306 HAMAMATSU PHOTONICS K.K.: COMPANY OVERVIEW
  • TABLE 307 HAMAMATSU PHOTONICS K.K.: PRODUCTS OFFERED
  • TABLE 308 HAMAMATSU PHOTONICS K.K.: PRODUCT APPROVALS, JANUARY 2021-JUNE 2024
  • TABLE 309 HAMAMATSU PHOTONICS K.K.: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 310 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 311 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 312 HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2024
  • TABLE 313 HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 314 SECTRA AB: COMPANY OVERVIEW
  • TABLE 315 SECTRA AB: PRODUCTS OFFERED
  • TABLE 316 SECTRA AB: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 317 SECTRA AB: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2024
  • TABLE 318 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 319 AKOYA BIOSCIENCES, INC.: PRODUCTS OFFERED
  • TABLE 320 AKOYA BIOSCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2024
  • TABLE 321 AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 322 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 323 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
  • TABLE 324 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 325 HOLOGIC, INC: COMPANY OVERVIEW
  • TABLE 326 HOLOGIC, INC: PRODUCTS OFFERED
  • TABLE 327 HOLOGIC, INC: PRODUCT APPROVALS, JANUARY 2021-JUNE 2024
  • TABLE 328 3DHISTECH LTD.: COMPANY OVERVIEW
  • TABLE 329 3DHISTECH LTD.: PRODUCTS OFFERED
  • TABLE 330 3DHISTECH LTD.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-JUNE 2024
  • TABLE 331 3DHISTECH LTD.: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2024
  • TABLE 332 APOLLO ENTERPRISE IMAGING CORP.: COMPANY OVERVIEW
  • TABLE 333 APOLLO ENTERPRISE IMAGING CORP.: PRODUCTS OFFERED
  • TABLE 334 APOLLO ENTERPRISE IMAGING CORP.: PRODUCT ENHANCEMENTS, JANUARY 2021-JUNE 2024
  • TABLE 335 APOLLO ENTERPRISE IMAGING CORP.: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 336 XIFIN, INC.: COMPANY OVERVIEW
  • TABLE 337 XIFIN, INC.: PRODUCTS OFFERED
  • TABLE 338 XIFIN, INC.: PRODUCT LAUNCHES, JANUARY 2021-JUNE 2024
  • TABLE 339 XIFIN, INC.: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 340 HURON DIGITAL PATHOLOGY: COMPANY OVERVIEW
  • TABLE 341 HURON DIGITAL PATHOLOGY: PRODUCTS OFFERED
  • TABLE 342 HURON DIGITAL PATHOLOGY: PRODUCT APPROVALS, JANUARY 2021-JUNE 2024
  • TABLE 343 HURON DIGITAL PATHOLOGY: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 344 HURON DIGITAL PATHOLOGY: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2024
  • TABLE 345 CORISTA: COMPANY OVERVIEW
  • TABLE 346 CORISTA: PRODUCTS OFFERED
  • TABLE 347 CORISTA: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 348 CORISTA: OTHER DEVELOPMENTS, JANUARY 2021-JUNE 2024
  • TABLE 349 INDICA LABS: COMPANY OVERVIEW
  • TABLE 350 INDICA LABS: PRODUCTS OFFERED
  • TABLE 351 INDICA LABS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2024
  • TABLE 352 INDICA LABS: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 353 OBJECTIVE PATHOLOGY SERVICES: COMPANY OVERVIEW
  • TABLE 354 OBJECTIVE PATHOLOGY SERVICES: PRODUCTS OFFERED
  • TABLE 355 OPTRASCAN, INC.: COMPANY OVERVIEW
  • TABLE 356 OPTRASCAN, INC.: PRODUCTS OFFERED
  • TABLE 357 OPTRASCAN, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2024
  • TABLE 358 OPTRASCAN, INC.: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 359 GLENCOE SOFTWARE, INC.: COMPANY OVERVIEW
  • TABLE 360 GLENCOE SOFTWARE, INC.: PRODUCTS OFFERED
  • TABLE 361 GLENCOE SOFTWARE, INC.: PRODUCT ENHANCEMENTS, JANUARY 2021-JUNE 2024
  • TABLE 362 AIFORIA TECHNOLOGIES OY: COMPANY OVERVIEW
  • TABLE 363 AIFORIA TECHNOLOGIES OY: PRODUCTS OFFERED
  • TABLE 364 AIFORIA TECHNOLOGIES OY: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 365 PAIGE AI, INC.: COMPANY OVERVIEW
  • TABLE 366 PAIGE AI, INC.: PRODUCTS OFFERED
  • TABLE 367 PAIGE AI, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-JUNE 2024
  • TABLE 368 PAIGE AI, INC.: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 369 PROSCIA, INC.: COMPANY OVERVIEW
  • TABLE 370 PROSCIA, INC.: PRODUCTS OFFERED
  • TABLE 371 PROSCIA, INC.: PRODUCT ENHANCEMENTS & APPROVALS, JANUARY 2021-JUNE 2024
  • TABLE 372 PROSCIA, INC.: DEALS, JANUARY 2021-JUNE 2024

List of Figures

  • FIGURE 1 DIGITAL PATHOLOGY MARKET
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
  • FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 7 DIGITAL PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION OF DANAHER CORPORATION
  • FIGURE 8 BOTTOM-UP APPROACH
  • FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN DIGITAL PATHOLOGY MARKET (2024-2029)
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 DIGITAL PATHOLOGY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 DIGITAL PATHOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 GEOGRAPHIC SNAPSHOT OF DIGITAL PATHOLOGY MARKET
  • FIGURE 17 RISING INCIDENCE OF CANCER AND GROWING ADOPTION OF PATHOLOGY SOLUTIONS FOR ENHANCED LAB EFFICIENCY TO DRIVE MARKET
  • FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 19 UK TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 20 ASIA PACIFIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 21 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 GLOBAL CANCER INCIDENCE, 2008-2030
  • FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015-2021
  • FIGURE 24 DIGITAL PATHOLOGY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 DIGITAL PATHOLOGY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 26 DIGITAL PATHOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 EUROPE: IVDR TIMELINE
  • FIGURE 28 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS, 2013-2023
  • FIGURE 29 MAJOR PATENTS FOR DIGITAL PATHOLOGY (2013-2023)
  • FIGURE 30 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS
  • FIGURE 32 MARKET POTENTIAL OF GENERATIVE AI IN ENHANCING DIGITAL PATHOLOGY ACROSS INDUSTRIES
  • FIGURE 33 IMPACT OF GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 34 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT
  • FIGURE 35 EUROPE: DIGITAL PATHOLOGY MARKET SNAPSHOT
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL PATHOLOGY MARKET
  • FIGURE 37 DIGITAL PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2023)
  • FIGURE 38 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 39 DIGITAL PATHOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 40 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 41 EV/EBITDA OF KEY VENDORS
  • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF DIGITAL PATHOLOGY VENDORS
  • FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 45 HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2023)
  • FIGURE 46 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 47 SECTRA AB.: COMPANY SNAPSHOT (2023)
  • FIGURE 48 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 50 HOLOGIC, INC: COMPANY SNAPSHOT (2023)